Theranostic cross-linking launches at Clinique Saint-Roch

The Montpellier launch of theranostic cross-linking, with intraoperative measurements of riboflavin and monitoring of its activation in progressive keratoconus.

Operating-theatre team with the theranostic cross-linking device at Clinique Saint-Roch
Theranostic cross-linking in use at Clinique Saint-Roch in Montpellier.

A launch in Montpellier

A post published on 12 November 2026 announces the launch of theranostic cross-linking at Clinique Saint-Roch in Montpellier. This development concerns patients with progressive keratoconus when cross-linking is indicated after an individual corneal assessment.

What the device measures

The device adds optical measurements during the procedure: it estimates corneal riboflavin concentration, monitors UVA-mediated photodegradation and calculates a score intended to describe the effect produced during treatment. This score is a device-specific intraoperative indicator; it does not by itself guarantee keratoconus stabilisation. Stabilisation is assessed by comparing serial corneal topography or tomography. [1–4]

Exclusive use of iontophoresis in my practice

In my practice, cross-linking is performed exclusively with iontophoresis and without epithelial removal. A low-intensity electrical current delivers riboflavin through an intact epithelium. This avoids a central epithelial wound and usually allows a faster return towards the pre-procedure level of vision, without removing other risks or the need for long-term follow-up. [5–7]

A measurement that complements corneal follow-up

Theranostic monitoring therefore complements the assessment performed during treatment; it does not change the indications for cross-linking or the postoperative checks that remain necessary. The detailed medical page explains how the technology works, the published evidence and its limitations.